-
DiDi Advances Robotaxi Operations in China with New R2 Vehicle and Expanded Safety Infrastructure
-
Smart Car Seats Tested: Do Sensors and Apps Actually Improve Safety?
-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
-
Pivotree Announces Third Quarter 2026 Results
-
Ur-Energy Commences Baseline Study Fieldwork; Nears Completion of Technical Report at Lost Soldier Uranium Project, Wyoming
-
ImageWorks Display Advances Whole-Store Solutions with a Re-Imagined Planniq Strong and Planniq Chill
-
Razavi Law Group Partners with Chapman University to Prepare the Next Generation of Attorneys
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
How to Turn Your Garage into Usable Living Space
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
The Next Healthcare Story Worth Telling May Be About Someone You Know
AimwellBio invites patients, colleagues and healthcare organizations to nominate professionals for consideration in its 2027 editorial coverage.
MIAMI, FL / ACCESS Newswire / November 17, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, is inviting the public to nominate physicians, medical researchers, scientists and other healthcare professionals for potential features as it plans its 2027 editorial coverage.
A physician finds a better way to reach patients who struggle to access care. A researcher moves a promising line of inquiry forward. A community practitioner tackles a health need that has gone overlooked. Patients and colleagues often see the impact of this work firsthand, and AimwellBio wants to hear from them.
Who should be nominated?
AimwellBio welcomes nominations from clinical medicine, biotechnology, medical research, pharmacy, rehabilitation, preventive care, healthcare technology and other areas of healthcare. Patients, colleagues, academic institutions, healthcare organizations and professional associations may submit nominations. Self-nominations are welcome.
Tell us what the person did, who their work serves and why it deserves a closer look. Where available, include links to publications, professional credentials, projects or other publicly verifiable information that helps document the contribution.
Nominations do not guarantee selection, publication, endorsement or participation in AimwellBio's professional network. Potential features are subject to review and editorial approval.
How to submit a nomination
Email [email protected] with the subject line Healthcare Professional Nomination. Include the professional's name, specialty, location, a short description of their contribution and, if available, a relevant public professional link. Do not include confidential patient information or private medical records.
About AimwellBio
AimwellBio, operated by Aimwell Partners Inc. (OTCID:AIMN), is a healthcare intelligence platform focused on source-traceable information, professional verification and the evaluation of healthcare and biopharmaceutical intelligence. Its offerings include AI visibility assessments, professional information resources and intelligence tools for qualified healthcare and research audiences. aimwellbio.com
Forward-Looking Statements
This release contains statements concerning potential future professional features, editorial activities and participation opportunities. These statements reflect current intentions and expectations, involve uncertainties and are not guarantees of future results. The timing, scope and outcome of any future initiative may change. Nominations do not establish professional standing, clinical quality or endorsement by AimwellBio.
Media and nominations: AimwellBio | Aimwell Partners Inc. (OTCID:AIMN) | [email protected] | aimwellbio.com
SOURCE: Aimwell Partners
View the original press release on ACCESS Newswire
T.Sanchez--AT